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ABSTRACT
Busulfan (1,4-butanediol dimethanesulfonate, BU) is relatively unique
among other standard chemotherapy compounds in its ability to deplete
noncycling primitive stem cells in the host and consequently to allow for
high levels of long-term, donor-type engraftment after bone marrow
transplantation (BMT). Such a property explains why this drug can be
used as an alternative to total body irradiation in preparative regimes for
BMT. However, as with radiation, BU conditioning is still troubled by
severe toxicities that limit its applications to suboptimal drug doses. These
problems stress the need for other BMT-conditioning drugs that are
better tolerated and more selectively targeted toward normal and malig-
nant hematopoietic stem cells. We have therefore compared the effects of
various novel dimethanesulfonate compounds (related to BU) in terms of
their toxicity to different stem cell subsets in vivo and in vitro and their
ability to provide for long-term donor bone marrow engraftment using the
congenic glucose-6-phosphate isomerase type 1 marker. Introduction of a
benzene or cyclohexane ring in some of these drugs affords rigidity to the
molecule and restricts the spatial positioning of the alkylating groups.
Among 25 different compounds thus far tested at single doses, PL63
[cis-1,2-(2-hydroxyethyl) cyclohexane dimethanesulfonate] proved to be
the most effective in providing for hematopoietic engraftment. The trans-
isomer of the same compound gave significantly less engraftment and was
comparable with the effects of dimethylbusulfan and Hepsulfam. The
engraftment data correlated well with the depletion of different bone
marrow stem cell subsets in the host as measured using the cobblestone
area forming cell assay. The extent of stem cell depletion could not be
explained on the basis of the distance and orientation of the two alkylating
groups. Pharmacokinetic data, however, indicate that there is a correla-
tion between biological activity and plasma levels reached.
The diverse cytotoxic effects shown by these novel analogues of BU have
provided a basis for relating biological activity with pharmacokinetic
properties rather than with structural properties such as distance and
orientation of the two alkylating groups. The identification of highly active
compounds such as PL63 offers an opportunity for further developing
other closely related drugs for potential application in clinical BMT
conditioning therapy.
INTRODUCTION
Recipient conditioning for BMT4 is an important determinant in the
overall clinical outcome in the treatment of many diseases of both a
malignant (acute and chronic leukemias, myelodysplastic syndrome)
as well as a nonmalignant nature (thalassemia major and inborn errors
of the immune system). The two most frequently applied regimens are
high-dose BU, followed by CY, or CY followed by TBI. In this
respect, it is important to note that BU and TBI share the relatively
unique property of depleting noncycling primitive stem cells and
consequently provide for long-term donor stem cell engraftment (1–
3). The efficacy of both preparative regimens in the treatment of
leukemias are similar, although there seems to be a small advantage
for CY/TBI in autologous transplantation for acute lymphoblastic
leukemias in terms of leukemia-free survival and relapse incidence (4)
and in patients with acute myeloid leukemia in first remission (5). In
the case of allogeneic BMT for chronic myeloid leukemia, the BU/CY
combination is slightly preferable over CY/TBI, both in terms of
tolerance and in clinical outcome (6), possibly because of the higher
antileukemic effect of BU/CY. Although better tolerated in some
cases, the use of BU as well as radiation for recipient conditioning is
still hampered by severe and in some cases lasting toxicities (Refs. 7
and 8; reviewed in Refs. 9 and 10). These toxicities include seizures
(11), veno-occlusive disease (7), and pulmonary complications (12).
The BU-induced hematological toxicities may not always be revers-
ible; hematopoietic recoveries can be impaired for up to 4 years after
BU treatment (13). Although damage to stromal cell populations are
often assumed to occur in patients after BU administration, its con-
tribution to impaired hematological reconstitution may be relatively
minor as compared with the direct and chronic effects on stem cells (3,
14). Because of the poor solubility of BU, an oral formulation is
needed, resulting in large variations in plasma concentrations between
patients. The plasma levels reached relate to the extent of toxicity and
graft rejection (11, 15–17) as well as to the probability of leukemic
relapse (18).
These factors illustrate the demand for new drugs that are at least as
effective and specific as BU and, preferably, show less toxicity. These
novel agents should be targeted toward both normal and malignant
primitive hematopoietic stem cells to allow for high levels of engraft-
ment with minimal risk of relapse. In the past decades, a number of
both aliphatic and aromatic DMS compounds have been synthe-
sized. Of the aliphatic compounds with the general formula
CH3zSO2Oz(CH2)nzOSO2zCH3, all compounds (including BU, n 5 4)
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n 5 2 (ethylene DMS), with a maximal activity with 1,6-hexanediol
DMS (n 5 6; Refs. 19 and 20). The cyclic DMSs synthesized
previously include cyclohexane-1,3- and cyclohexane-1,4-dimethane-
sulfonate (21), but these compounds have not been tested on their
ability to deplete bone marrow stem cells. Although DNA-DNA
cross-linking is often considered to be the toxic lesion, DNA-protein
binding has also been reported (20), mainly between DNA and the
cysteine of histone H3 (22). The in vitro or in vivo toxicity of the
aliphatic and cyclic DMSs or sulfamates synthesized to date has been
determined on either peripheral blood cells (23, 24), tumor cell lines
(25–27), tumor xenografts (20, 28, 29), primary chronic myeloid
leukemia cells (30), and spleen colony-forming units (31). In addition
to BU, only three DMS and sulfamate compounds have actually been
clinically evaluated: DMB (32), Treosulfan (33, 34), and Hepsulfam
(35).
In the present study, we compared the efficacy of host pretreatment
with 25 different aliphatic and cyclic analogues of BU, which have
either been described before (20, 28, 29) or synthesized recently.
These compounds were tested for induction of short- and long-term
donor bone marrow engraftment in vivo using the Gpi-1 congenic
marker and their ability to deplete various host stem cell subsets, as
defined in the CAFC assay in vitro. In addition to syngeneic BMT,
engraftment of allogeneic bone marrow was evaluated after condi-
tioning regimens that included BU and another active compound,
PL63, in combination with CY.
MATERIALS AND METHODS
Animals
Male C57BL/6JIco (B6-Gpi-1b/Gpi-1b) mice (IffaCredo, L’Arbresle,
France), 12–20 weeks of age, 25–30 g, were used as recipients. C57BL/6J-
Gpi-1a/Gpi-1a (B6-Gpi-1a) congenic mice (males) were used as a source of
donor bone marrow. BALB-B10LiLa male mice (Jackson Laboratory, Bar
Harbor, ME), also carrying the Gpi-1a gene, were used as allogeneic donors
that were H-2-matched (H-2b) but mismatched on a number of minor histo-
compatibility loci. For the pharmacokinetic studies, groups of five to six
C57BL/6 mice from either congenic strain were used for each time point.
Animals were housed in approved facilities free of known pathogenic organ-
isms (Sendai, MHV, PVM, GD VII, REO III, EMC, LMC, MVM, K, and
Mycoplasma pulmonis). Experiments were performed in accordance with the
Netherlands Experiments on Animals Act (1977) and the European Conven-
tion for the protection of vertebrate animals used for experimental purposes
(Strasbourg, 18.III.1986).
Drugs
BU and CY were purchased from Sigma Chemical Co. (St. Louis, MO) and
Aldrich-Chemie (Steinheim, Germany), respectively. The sulfamate derivative
Hepsulfam (NSC 329680) was obtained from the Drug Synthesis and Chem-
istry Branch of the National Cancer Institute (Bethesda, MD). Treosulfan was
a gift from Dr. J. Baumgart (Medac Hamburg, Hamburg, Germany). All other
DMS or sulfamate compounds were synthesized within our own facilities
(Department of Experimental Chemistry, Paterson Institute for Cancer Re-
search, Manchester, United Kingdom), partly as described previously: PL51,
PL50, PL49, and PL48 (20), PL26 (28), and PL84 and PL87 (29). The
chemical structure of all compounds used in this study are shown in Fig. 1 for
aliphatic (a), aromatic (b), and alicyclic (c) compounds.
In Vitro Treatment
Murine bone marrow cells were isolated from femurs from untreated mice
and incubated in Iscove’s modified Dulbecco’s medium (Life Technologies,
Inc., Breda, the Netherlands) supplemented with penicillin (100 units/ml),
streptomycin (100 mg/ml), 100 mM b-mercapto-ethanol, 10% FCS, and 5%
horse serum. Nucleated cells were incubated at 37°C (106/ml) with the appro-
priate drug for 18 h at a concentration of 30 mM. The concentration of the
solute DMSO never exceeded 1%.
In Vivo Treatment
All drugs were injected i.p. in volumes of 0.1 ml/10 g of body weight. DMB
was dissolved in 5% DMSO in PBS, PL109 and Treosulfan in 50% DMSO in
PBS, and CY in PBS. All other drugs were administered as a suspension in
corn oil. TBI was applied using a 137Cs gamma irradiation unit (IBL 637; CIS
Biointernational, Gif-sur-Yvette, France) to a dose of 7 Gy (87 cGy/min). Each
treatment group consisted of four mice allocated for the CAFC assay and/or
five to six mice for bone marrow transplantation. When mice were treated with
BU or PL63 combined with CY, BU or PL63 was given at day 2, CY at day
1, followed by BMT at day 0. Fractionated BU (4 3 25 or 4 3 12.5 mg/kg)
was administered on four consecutive days (day 4 until day 1), followed by
BMT at day 0.
Animals treated with TBI, CY, and PL63 received neomycin sulfate in their
drinking water (3.5 g/l) to prevent treatment-related gut damage (2). Because
of incisor damage starting 2–3 months after the administration of Hepsulfam,
PL63, or CY, mice were provided moistened food from week 6 onward to
prevent malnutrition.
Determination of Hematopoietic Stem Cell Subset Frequencies in Vitro
(CAFC Assay)
At 24 h after drug treatment, bone marrow cells were harvested from either
pooled groups of four mice or from conical tubes used for in vitro treatments
and plated in limiting dilutions on confluent layers of the bone marrow stromal
cell line FBMD-1 in 96-well plates, as described previously (36–38). These
cultures provided growth of hematopoietic precursors under the stromal layer,
giving the appearance of cobblestone areas in phase-contrast microscopy. The
Fig. 1. Structural formulas of the aliphatic (a), aromatic (b), and alicyclic (c) analogues
of BU that were investigated in the present study.
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frequency of CAFCs were assessed weekly from day 7 until day 35 after
overlay. This in vitro system provided an estimate of the surviving fraction of
CAFC day types that correspond to CFU-GM (CAFC day 5), transiently
repopulating CFU-S day 12 (CAFC day 10), and the primitive stem cells with
long-term repopulating ability (CAFC days 30–40; Refs. 36, 38, and 39).
BMT and Determination of Donor Engraftment in Vivo
(Gpi-1 Chimerism Assay)
At 24 h after the drug treatments, allocated mice were transplanted i.v. with
106 nucleated bone marrow cells freshly harvested from the tibia and femur of
B6-Gpi-1a or BALB.B10 donor mice. The level of erythroid chimerism in
blood samples obtained at different intervals between 2 and 36 weeks after
transplant was determined from glucose phosphate isomerase (Gpi-1) electro-
phoresis as described previously (40).
Pharmacokinetic Properties of BU Analogues
C57BL/6JIco or C57BL/6J mice were treated with BU (50 mg/kg), PL63
(50 or 300 mg/kg), PL26 (300 mg/kg), or PL108 (150 mg/kg). All drugs were
i.p. administered. At the indicated time points, mice were anesthetized with
isoflurane and bled, either by heart puncture or from the intraorbital cavity.
Blood was collected in heparinized tubes and centrifuged, after which the
plasma was collected and frozen at 280°C until analysis.
Determination of Serum Levels of BU Analogues
BU. Two hundred ml of the serum samples were diluted with PBS to a
volume of 500 ml and were then spiked with deuterated BU as an internal
standard and extracted as described below. The concentration of BU in the
sample was then determined by comparing the ratio of BU and deuterated BU
peaks.
BU Analogues. Two hundred ml of each sample were again diluted with
PBS to give a volume of 500 ml and extracted as described below. In these
cases, a standard curve of the analogue in question was prepared in mouse
serum immediately prior to drug estimation and extracted simultaneously with
the samples. This was used to determine the serum concentration of the
analogue.
Sample Extraction. Sample extraction was by solid phase; briefly, a
cyano-propyl SPE cartridge (Waters-Millipore, Watford, United Kingdom)
was conditioned with 3 ml of methanol, followed by 3 ml of 50% methanol in
water. The sample containing the compound in question was loaded onto the
cartridge and allowed to equilibrate on the cartridge for 1 min. The cartridge
was washed with 1 ml of water, and the analyte eluted with 1 ml of acetonitrile.
Chromatography. Extracted samples (40 ml) were analyzed by high-
performance liquid chromatography using an Asahipak ODP50 analytical
column (150 3 4.6 mm) using an isocratic mobile phase (70% methanol, 30%
water, 0.1 M ammonium acetate). Detection was by thermospray mass spec-
trometry in selected ion recording mode.
Determination of the Internucleophile Distances of BU Analogues
These were calculated using a Silicon Graphics Iris 4d/310GTX Worksta-
tion using Quanta 4.0 software (including Charm 22.2) working under IRIS
4.0.5, as described previously (41).
Determination of the Partition Coefficients of BU Analogues
The experimental value of the partition coefficient of some of the com-
pounds was determined using the colorimetric method monitoring the blue
pigment formed by the reaction of alkane sulfonate with 4-nitrobenzylpyridine
(NBP; Ref. 42). BU and other drugs were dissolved in a minimum volume of
DMSO (,1%) and made up to 1 mg/ml in octanol. Serial dilutions were made
in octanol. Five ml of each solution were mixed with 5 ml of deionized water
and mixed for 30 min on a mechanical rotator. Aliquots (1 ml) of both aqueous
and organic layer were removed, and 2 ml of 2% NBP in ethylene glycol were
added, and the solution was boiled for 30 min. This was then cooled on ice, 2
ml triethylamine (50% w/v in acetone) were added, and the blue color was
assayed at 565 nm. All concentrations were calculated using a standard curve.
Experiments were performed in duplicate over a range of seven concentrations
from 0.05 to 1 mg/ml. The theoretical partition coefficients were calculated
from the structure of these compounds using the software package ClogP 4.0
(BioByte Corp., Claremont, CA).
RESULTS
Three assays were used to evaluate the biological activity of the
various compounds: in vivo treatment of mice followed by either
BMT or CAFC assay or in vitro treatment of freshly isolated murine
bone marrow cells followed by the CAFC assay. Table 1 summarizes
in which assay the various compounds were evaluated.
In Vitro Sensitivity of Murine Bone Marrow toward Different
BU Analogues. Fig. 2 shows the levels of CAFC survival after an
18-h incubation of marrow cells with 30 mM of each compound. A
number of agents showed moderate activity that was comparable with
that of BU. These include DMB, Hepsulfam, PL26, PL103, PL104,
and PL106. The four compounds that appeared to exceed the activity
of BU were Treosulfan, PL63, and PL64, whereas PL102, PL109, and
PL107 had very little cell killing effect. These in vitro results after
treatment at equimolar concentrations were compared with CAFC
subset depletion and donor marrow engraftment after in vivo treatment
so as to isolate possible differences in pharmacokinetic properties
among the various compounds.
Toxicity. A number of different dose levels for each new com-
pound was applied in pilot studies to establish a dose that approxi-
mated to the MTD. The dose levels and animal survival for each
different compound is listed in Table 2. Large differences in dose exist
between some of the compounds, e.g., 12 mg/kg for DMB and 3000
mg/kg for Treosulfan. However, for the majority of the cyclic com-
pounds, the MTD was reached at doses of ;300 mg/kg. The toxicities
that were encountered included: (a) supra-acute toxicity within the
first day (lethargy, hypothermia), which was the dose-limiting toxicity
for most drugs except DMB and Hepsulfam; (b) gut damage (diarrhea
between 1 and 3 weeks) was seen for PL63 and Hepsulfam; and (c)
incisor damage started 6 weeks after CY, PL63, or Hepsulfam admin-
istration or the combinations PL63/CY or BU/CY. The extent of this
latter damage was such that the animals were provided moistened
food to avoid malnutrition.
Liver and kidney toxicity were determined by measuring ALAT
Table 1 Assays used for each compound
Compound
In vitro In vivo
CAFC assay CAFC assay BMT
Busulphan 1 1 1
DMB 1 1 1
PL109 1 1 1
Hepsulfam 1 1 1
Treosulfan 1 1 1
PL102 1 1 1
PL48 1
PL49 1
PL50 1
PL51 1
PL26 1 1 1
PL84 1
PL87 1 1
PL32 1 1 1
PL33 1 1
PL34 1 1 1
PL35 1 1
PL39 1 1
PL40 1 1
PL63 1 1 1
PL64 1 1 1
PL103 1
PL104 1 1
PL106 1
PL107 1
PL108 1 1
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and BUN, respectively, in plasma of control and treated animals.
Control levels of ALAT ranged from 14.5 to 18.6 IU/l within a range
between 2 days and 36 weeks after transplant. Within that time frame,
BUN varied between 8.57 and 10.12 mmol/l. Neither ALAT nor BUN
values changed after treatment with either DMB, Hepsulfam, PL26,
PL63, PL64, PL87, or TBI (7 Gy).
Host CAFC Depletion and Syngeneic Donor Marrow Engraft-
ment. The extent of depletion of the various stem cell subsets in the
host as measured in the CAFC assay differed widely among the 25
compounds tested. Figs. 2 and 3 contain data of a number of com-
pounds (aliphatic and cyclic, respectively) that were tested in both the
CAFC and syngeneic bone marrow transplantation. The depletion of
primitive hematopoietic cells (CAFC day 35; Fig. 3a and 4a) appeared
to be reflected in the subsequent engraftment of donor bone marrow
cells (Figs. 3b and 4b). PL102, the epoxide analogue of BU, showed
little in vivo activity, whereas PL109, the sulfamate analogue of BU,
showed comparable engraftment levels to BU, although the CAFC
data indicate a lower activity in the depletion of stem cells. The other
aliphatic BU analogues with carbon chain lengths of 5–8 (PL51,
PL50, PL49, and PL48, respectively) were also tested in both assays
but appeared to be inactive (Table 2).
Only one compound exceeded BU in its ability to deplete CAFC
day 35, the cis-cyclohexane analogue PL63. This compound also
proved to be as equally effective as 7 Gy irradiation in depleting early-
and late-developing CAFC subsets and in providing for long-term
donor marrow engraftment. The trans-isomer PL64 gave moderate
stem cell toxicity and engraftment levels that were comparable with
the effects of DMB and Hepsulfam. The other cyclic analogues PL26
(Fig. 3), PL32, PL33, PL34, PL35, PL39, PL40, PL84, and PL87
(Table 2) were less effective in depleting stem cell subsets in the
CAFC assay and showed minimal long-term syngeneic bone marrow
engraftment.
When BU was administered in four daily doses of 12.5 mg/kg each,
the overall profile of depleting the various hematopoietic subsets as
measured with the CAFC assay was comparable with a single dose of
1 3 50 mg/kg (Fig. 5a), indicating an additive effect of fractionation.
However, fractionation enabled at least a doubling in the tolerated dose
and a further decline in the survival of primitive hematopoietic stem cells
to below detection limits (,0.05%). This difference is also reflected in
the level of engraftment of syngeneic bone marrow cells: 85% versus
50% for fractionated and single dose, respectively (Fig. 5b).
Fig. 6a shows how the level of CAFC day 35 survival in the host
inversely relates to the magnitude of long-term donor blood chimer-
ism for each pretreatment group, whereas the large scatter in data
points in Fig. 6b shows a poor correlation with the level of CAFC
survival after in vitro treatment.
Allogeneic BMT. BU and PL63, the analogue with the highest
activity in syngeneic BMT, were also evaluated for their ability to
provide for chimerism in an H-2-matched allogeneic BMT model
(BALB.B10 transplanted into C57BL/6J). A fractionated course of
BU (4 3 25 mg/kg) had a transient benefit over a single dose but did
not allow for permanent donor marrow engraftment (Fig. 7a). Similar
results were obtained after a single dose treatment with PL63 (300
mg/kg). Fractionation with concomitant increase of the dose was not
possible for PL63 because this appeared to be too toxic. Transplan-
tation of allogeneic bone marrow after conditioning with BU or PL63
combined with CY (200 mg/kg) were also performed. In this case,
single-dose BU plus CY was not sufficient to overcome the immu-
nological barrier resulting in immediate allograft rejection, whereas
fractionated BU or single-dose PL63 combined with CY allowed for
lasting and high levels of donor marrow engraftment after allogeneic
BMT (100 and 80% after 20 weeks, respectively).
Chemical Properties of BU Analogues. Internucleophile dis-
tances were determined to establish whether there was a relationship
biological activity and molecular structure. In this case, comparisons
with the in vitro activity seems the most appropriate so as to exclude
pharmacokinetic processes that could influence biodistribution to the
target tissues. Table 3 shows the distance between the two alkylating
carbons varied between 3.03 Å (PL32) and 7.63 Å (PL108). Com-
pounds with comparable or higher activity than BU, e.g., PL26, PL63,
PL64, PL106, and PL108, have a wide range of internucleophile
distances whereas compounds lacking any activity, e.g., PL32 and
PL33, have internucleophile distances that are almost identical to BU.
The distances between the two oxygens in the neighboring mesylate
groups were also estimated because these atoms are likely to be
occupied by a nitrogen or oxygen of a nucleophile (e.g., guanine in
DNA). Again, the distances between active (PL63 and PL64, 3.27 and
3.24 Å, respectively) and inactive compounds (PL32 and PL34, 3.12
and 3.52 Å, respectively) do not differ significantly. Thus, it seems
that the distances between the two leaving groups of the compounds
tested do not correlate with the biological activity.
Partition Coefficients. The values for the partition coefficients
were determined using either an experimental or a computer calcula-
tion method. Experimental values were determined using a range of
concentrations, and the coefficients were taken from the linear part of
the curves. The values are depicted in Table 3. In the cases in which
we were unable to determine the experimental values because of lack
of material, a theoretical calculation was made for the partition coef-
ficients. Although the calculated values were mostly higher than the
Fig. 2. CAFC frequencies (percentage of control) of murine bone marrow cells treated
in vitro with the indicated drugs (18 h, 30 mM).
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experimentally determined values, both approaches do correlate (Spear-
man’s ranking, correlation coefficient, 0.84; P 5 0.009; not shown).
Pharmacokinetics. Table 4 shows some pharmacokinetic proper-
ties of BU, PL63, PL26, and PL108. The average AUC after a single
dose (50 mg/kg) of BU was 133 mgzh/ml. The AUC after an equal
dose of PL63 was much lower (50.5 mgzh/ml), whereas it was com-
parable with that of BU at a higher dose approximating the MTD (300
mg/kg). The AUC after 300 mg/kg PL26 was again much lower than
after an equal dose of PL63. PL108 gave the lowest AUC of the four
compounds listed in this table; the AUC at 150 mg/kg is 3-fold lower
than BU at one-third of the dose (50 mg/kg). From the AUCs, the
relative bioavailabilities (Fr) were calculated. The Fr of PL63 at 300
mg/kg was five times lower as compared with BU. The Fr of PL26 at
300 mg/kg and PL108 at 150 mg/kg were ;10-fold lower as com-
pared with BU.
DISCUSSION
Previous studies on different chemotherapeutic agents and radiation
modalities have demonstrated that depletion of primitive stem cells in
the recipient is an important prerequisite to achieving lasting engraft-
ment of both transiently and long-term repopulating stem cells from
Table 2 Summary of data (d35 CAFC survival and percent engraftment) in mice treated with different compounds
Compound
Carbon
chain
length
Dose
(mg/kg) Carrier Survival
Survival
time
d35 CAFC
survival
(%)
% donor
engraftment
(20 wk)
Busulfan [C-4] 50 Oil 4/5 ,1 day 0.67 49.2 6 3.4
50 Oil 2/4 ,1 day 0.69
4 3 25 Oil 5/5 ,0.05 87.5 6 4.1
DMB [C-4] 12 5% DMSO in PBS 5/5 2.9a 39.7 6 4.7
12 Oil 5/5 3.2a 38.5 6 5.3
12 5% DMSO in PBS 5/5 2.1 30.1 6 6.6
PL109 [C-4] 100 5% DMSO in PBS 3/3
300 Oil 3/3
600 Oil 3/3
600 50% DMSO in PBS 5/5 4.66 52 6 2.7
Hepsulfam [C-7] 100 Oil 5/5
150 Oil 3/3
200 Oil 5/5 4.9 31.9 6 4.8
200 Oil 5/5
Treosulfan [C-4] 3000 50% DMSO in PBS 4/4
3000 5/5 21.7 6.54 6 2.2
5000 0/3 ,1 day
PL102 [C-4] 600 Oil 4/4 101.8 0
PL48 [C-8] 100 Oil 4/4 19.1 17.9a
200 Oil 0/3 6–8 days
PL49 [C-7] 100 Oil 4/4 19.4 17.8a
200 Oil 1/3 2 h 1 8 wk
PL50 [C-6] 100 Oil 3/3
100 Oil 4/4 10.0 25.5a
200 Oil 0/3 ,2 h
PL51 [C-5] 50 Oil 3/3
50 Oil 4/4 9.1 26.5a
100 Oil 2/3 3 h
PL26 [C-6] 300 Oil 5/5 49.6 5.2 6 1.4
300 Oil 5/5
400 Oil 0/3 ,1 day
PL84 [C-7] 300 Oil 5/5
400 Oil 2/3 ,1 day 68.0a 3.1 6 0.3
PL87 [C-8] 400 Oil 3/3
600 Oil 4/5 ,1 day 41.5 8.8 6 1.1
PL32 [C-6] 300 Oil 3/3
300 Oil 8/10 ,1 h 110.1 0
PL33 [C-6] 300 Oil 3/3
300 Oil 9/10 ,2 h 75.4 0
PL34 [C-8] 300 Oil 3/3
300 Oil 9/9 123.9 0
PL35 [C-8] 300 Oil 4/4
300 Oil 9/9 78.3 4.2 6 2.5
PL39 [C-7] 300 Oil 4/4 34.6 11.1a
PL40 [C-7] 300 Oil 3/3
300 Oil 9/9 80.5 0
PL63 [C-6] 200 Oil 5/5 0.4a 63.6 6 5.9
300 Oil 10/11 10 days 0.57 70.2 6 5.6
400 Oil 2/3 8 days
400 Oil 4/5 6 days 0.03a 90.7 6 8.0
400 Oil 6/7 8 days 0.04a 88.4 6 7.1
PL64 [C-6] 200 Oil 5/5 14.2a 21.5 6 6.3
300 Oil 5/5 3.8 34.9 6 6.0
400 Oil 3/3
400 Oil 4/4 2.7a 40.8 6 2.4
PL104 [C-7] 300 Oil 2/4 ,1 day 13.1 22.3a
PL108 [C-8] 150 Oil 3/3 28 13.5a
200 Oil 1/3 ,1 day
300 Oil 1/3 ,1 day
TBI 4 Gy 5/5 30.4
5 Gy 5/5
7 Gy 5/5 0.43 67.6
a Values were calculated according to the curve in Fig. 5 (formula: y 5 226.67x 1 52.13).
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the donor (2, 3, 43). Among the standard chemotherapeutic drugs, BU
was found to be particularly efficient in this respect, and it is therefore
of interest in the present study to establish whether a relationship
exists between the molecular or physical properties of new BU ana-
logues and their biological activity in the context of BMT condition-
ing therapy. Our design of new compounds was first based on earlier
findings that the antitumor activity of BU analogues changed accord-
ing to the distance and orientation of the two methane-sulfonate
groups (28, 29, 44). Many of these compounds contained either a
cyclohexane or benzene ring, thus rendering rigidity to the molecule
and restricting the positioning of the alkylating groups.
The present study shows that there is indeed a large variation in
activity among the group of closely related BU analogues, although
there does not seem to be a correlation between the spacing or
orientation of the two methane-sulfonate or -sulfamate groups and
their biological activity. We decided to use these drugs at doses that
were equitoxic to the animals rather then using the same dose for
every drug because almost all drugs tested in vivo did not show any
activity at the dose normally used for BU (50 mg/kg). Figs. 2a and 3a
show that of the compounds tested, only PL63 exceeded the activity
of BU in depleting primitive stem cells. Indeed, PL63 had a similar
effect to 7 Gy TBI in its ability to diminish the number of transiently
repopulating stem cells (CAFC days 7–14) as well as the primitive
stem cell population (CAFC day 35). Albeit lower in activity than BU,
Hepsulfam, DMB, and PL109 showed a 1–2-log depletion of late-
developing CAFCs. PL109 was designed to be a more soluble drug as
compared with BU through replacement of the methane-sulfonate
moieties by sulfamate groups. However, it required a 12-fold increase
in dose compared with BU to achieve a similar level of stem cell
depletion. Other members of the aliphatic series with varying length
of the carbon chain were at least 10-fold less active than BU. This is
in accordance with a previous report in which the biological activity
of a series of dimethane sulfonate compounds (n 5 1–10) was
measured from the assessment of marrow CFU-S content in rats (31).
Fig. 4. CAFC frequencies (percentage of control; a) and development of bone marrow
chimerism after syngeneic BMT (b) of mice treated with cyclic analogues of BU. Doses
of all three drugs were 300 mg/kg. Values in b are the means of four to six mice; bars,
61 SE.
Fig. 5. CAFC frequencies (percentage of control; a) and development of bone marrow
chimerism after syngeneic BMT (b) of mice treated with BU, either a single dose (1 3 50
mg/kg) or fractionated (4 3 12.5 or 4 3 25 mg/kg). Values in b are the means of four to
six mice; bars, 61 SE.
Fig. 3. a, CAFC frequencies (percentage of control) of mice treated with BU, aliphatic
analogues of BU (Treosulfan, PL109, Hepsulfam, and DMB), and TBI. For determination
of CAFC, bone marrow was harvested from treated and control mice 24 h after treatment,
pooled, and seeded onto confluent layers of murine stromal cells. Doses were as follows:
Treosulfan, 3000 mg/kg; PL109, 600 mg/kg; Hepsulfam, 200 mg/kg; DMB, 12 mg/kg;
BU, 50 mg/kg; and TBI, 7 Gy. b, development of bone marrow chimerism after syngeneic
BMT (106 B6-Gpi-1a bone marrow cells) in mice treated as in a. Values are the means of
four to six mice; bars, 61 SE.
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The epoxide analogue studied in this paper (PL102) did not show
any activity in our assay systems. Various epoxide analogues have
been synthesized previously, but neither of them is more active than
BU in depleting the neutrophils, lymphocytes, or platelets (45). Treo-
sulfan is a registered prodrug indicated for recurrent or progressive
ovarian cancer (34). This compound is spontaneously converted into
corresponding mono- and diepoxides responsible for alkylation (46,
47). It is as yet unclear why the metabolite of Treosulfan seems to be
more active in stem cell depletion as compared with the mono-
epoxide PL102.
Our data show that the spacing between the two alkylating groups
does not bear a relationship with cytotoxicity. This is exemplified by
the fact that sulfamate analogues of BU and PL49, i.e., PL109 and
Hepsulfam, respectively, show a decreased activity while the carbon-
chain length is the same. The cyclic analogues also show large
variations in activity with relatively minor structural differences be-
tween compounds. There is, for instance, a large difference in activity
between PL63 (cis-1,2-(2-hydroxyethyl) cyclohexane DMS and its
trans- counterpart (PL64). Also, replacing the cyclohexane ring of
PL63 by a benzene ring (PL26) almost fully diminishes the in vivo
activity of the BU analogue. In both compounds, the spacing is
virtually the same, as is the orientation of both side groups. The cyclic
compounds that are particularly inactive are PL32, 33, 34, 35, 39, 40,
84, and 87, although the internucleophile distances of the more rigid
molecules PL32 and PL33 are the same as in BU, and the internu-
cleophile distance of PL34 is similar to that of PL63. It thus appears
that factors other than spacing and orientation of the two alkylating
groups are of major importance.
In addition to single-dose BU, we also treated mice with a more
clinically relevant scheme: four smaller doses administered over four
Fig. 7. Development of donor-type chimerism after allogeneic BMT (106 BALB.B
bone marrow cells) in B6 mice pretreated with BU and PL63 without (a) or with (b) CY.
Values are the means of four to six mice; bars, 61 SE.
Fig. 6. a, correlation between percentage of host CAFC day 35 survival in murine bone
marrow and donor engraftment 20 weeks after syngeneic BMT in mice treated with
various BU analogues. The formula of the straight line is: y 5 226.67x 1 52.13, and has
been used to calculate some theoretical values for Table 2. b, relationship between CAFC
day 35 survival after in vitro versus in vivo treatment for each compound.
Table 3 Summary of chemical properties of DMS compounds
Compound
Partition coefficient (log P)
Internucleophile
distance (Å)
Calculated
Experimental
(SD) C–C O–O
Busulphan 20.59 20.585 (0.007) 3.09 2.93
DMB 0.03 3.93 4.68
PL109 22.25 3.91 6.13
Hepsulfam 5.32 4.66
Treosulfan 22.20 3.91 6.15
PL102 20.45 3.89 5.38
PL48 1.52 8.91 11.09
PL49 0.995 0.413 (0.061) 7.64 9.88
PL50 0.466 0.146 (0.082) 6.42 8.66
PL51 20.063 20.109 (0.009) 5.08 7.37
PL26 0.746 0.535 (0.077) 4.04 3.85
PL84 1.28 5.36 6.71
PL87 1.804 1.352 (0.009) 6.62 8.85
PL32 0.83 3.03 2.83
PL33 0.83 3.07 3.12
PL34 0.99 0.470 (0.056) 4.88 3.52
PL35 0.66 5.84 6.78
PL39 0.66 5.03 5.02
PL40 0.66 4.56 4.77
PL63 2.048 0.757 (0.213) 4.66 3.27
PL64 2.048 0.925 (0.009) 4.65 3.24
PL103 2.05 6.29 8.40
PL104 2.05 5.26 6.03
PL106 1.49 4.51 6.46
PL107 1.49 4.69 6.17
PL108 2.05 7.63 8.23
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consecutive days. The effect of dividing the dose over 4 days
(4 3 12.5 mg/kg) produced an additive effect; the depletion of the
different hematopoietic subsets was very similar to those seen after a
single dose of 50 mg/kg. However, fractionation of the dose did allow
for a doubling of the dose (4 3 25 mg/kg) without compromising its
toxicity. This dose escalation had a profound effect on stem cell
killing; CAFC frequencies fell below detectable levels (.0.05%) after
2 weeks in culture. This decrease is again reflected in the ability to
allow for high levels of syngeneic donor marrow engraftment.
In the allogeneic setting, both single-dose PL63 and fractionated
BU were also very active in allowing for high and permanent levels of
engraftment but only when used in combination with CY. The benefit
of adding CY to either TBI or BU prior to allogeneic BMT in terms
of promoting donor-type chimerism is well recognized in animal
models (48–50) and is most likely attributed to the immune suppres-
sive properties of CY in preventing allograft rejection. Although it is
difficult to discern whether fractionated BU or PL63 also contributed
to immune suppression, the lack of allogeneic chimerism in mice
given single-dose BU with CY may reflect insufficient stem cell
ablation that is required for donor cell engraftment across the immu-
nological barrier used here.
Thus far, we have evaluated the activity of these compounds using
two biological end points: depletion of CAFC subtypes and blood
chimerism after BMT in treated animals. Femoral CAFC (day 35)
depletion directly after treatment with a variety of DMS compounds
shows a highly significant correlation with development of donor
marrow engraftment in the months thereafter (Fig. 6a). The data
strongly suggest that the extent of depletion of primitive stem cells
(CAFC day 35) fully determines the establishment of primitive donor
stem cells with long-term repopulating ability. Therefore, the in vitro
CAFC assay system alone may be sufficient for the initial identifica-
tion of new compounds that have the ability of promoting long-term
chimerism in pretreated recipients.
We tested a number of drugs for their activity in vitro in which
fresh bone marrow cells were treated with equimolar concentrations
of drug as opposed to equitoxic doses used in vivo. These in vitro
treatments of murine bone marrow cells may answer the question as
to whether in vivo distribution is an important determinant in the
efficacy of these compounds. Indeed, we found that a number of
compounds exhibited relatively high in vitro activity but with poor
activity in vivo. These include Treosulfan, PL26, and PL108. With
respect to molecular structure, it is important to note that of the cyclic
compounds that show the highest activity (.90% depletion of CAFC
day 35) are all analogues with two hydroxyethyl moieties (n 5 2)
attached to the ring. It seems that the distance between the active
groups and the cyclohexane ring to which they are attached is more
important than the distance between the active groups themselves;
PL108, PL64, and PL63 show higher activity as compared with their
methane-sulfonate counterparts PL35, PL33, and PL32. The differ-
ences between the in vitro and in vivo activities can be reconciled, at
least partially, by the pharmacokinetic profiles of four tested com-
pounds. From the drug levels measured in the blood, it appeared that
the AUC of PL63 was 2.5-fold lower as compared with BU after the
same dose. AUCs were comparable when the dose of PL63 was 6-fold
higher than BU, and this is in keeping with the higher stem cell
activity based on the in vitro treatment experiment. PL26 given at a
dose of 300 mg/kg results in an AUC that is 2-fold lower than that of
PL63 at the same dose. From the AUCs, relative bioavailabilities (Fr)
were calculated. At an equal dose of 50 mg/kg, the Fr of PL63 was
2.5-fold lower than BU, and at a higher dose of 300 mg/kg, the Fr
further decreases to 20%. The Fr of PL26 at 300 mg/kg and PL108 at
150 mg/kg were even lower, ;10% of the value for BU. The com-
parison between bioavailability among these four compounds is there-
fore consistent with the lower activity in vivo as compared with in
vitro.
In conclusion, a wide range of stem cell toxicities for different BU
analogues was seen that correlated with their ability to induce donor-
type chimerism after BMT. The compounds BU, PL63, PL26, PL108,
and Treosulfan showed a comparable activity in vitro. However,
significant activity in vivo was only seen for BU and PL63, which
correlated with the bioavailability at the MTD. There seems to be no
clear correlation between biological activity and either internucleo-
phile distance or partition coefficient. The high levels of engraftment
reached with the use of PL63 in syngeneic or allogeneic BMT and the
activity of some of these analogues in vitro demonstrate the potential
for improving the selectivity of this class of compound in BMT
conditioning therapy. Such an approach is becoming increasingly
pertinent to the current clinical efforts of establishing less toxic,
pretransplant protocols that favor the growth of donor stem cells and
consequently establish lymphohematopoietic chimerism.
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